| Variant | Gene | Risk Allele | Score vda | Association Type | Original DB | Sentence supporting the association | PMID | PMID Year | ||
|---|---|---|---|---|---|---|---|---|---|---|
|
0.080 | GeneticVariation | BEFREE | Three single-nucleotide polymorphisms (C1236T, G2677T/A, C3435T) and/or mRNA expression changes of ABCB1 gene were demonstrated to be associated with inter-individual variability of imatinib response in CML patients. | 28836054 | 2017 |
||||
|
0.080 | GeneticVariation | BEFREE | MDR1-C3435T genotype might emerge as a potential biomarker to predict the risk of cytogenetic relapse in patients with CML. | 28367681 | 2017 |
||||
|
0.080 | GeneticVariation | BEFREE | We therefore studied three polymorphisms (C1236T, G2677T and C3435T) in the human multidrug-resistance gene (MDR1) in 86 patients with chronic myeloid leukaemia treated with imatinib. | 27294449 | 2016 |
||||
|
0.080 | GeneticVariation | BEFREE | Genetic polymorphisms in CYP3A5*3 and ABCB1 C3435T are associated with TPC in CML patients in this population. | 27426203 | 2016 |
||||
|
0.080 | GeneticVariation | BEFREE | In conclusion, this meta-analysis suggests that c.1236C>T, c.2677G>T/A and c.3435C>T can be served as predictive markers for the therapeutical use of imatinib in CML patients. | 25245580 | 2015 |
||||
|
0.080 | GeneticVariation | BEFREE | However, no significant association was found for the MDR1 G2677T or C3435T polymorphisms in an Asian CML population as well as a Caucasian CML population. | 24798723 | 2014 |
||||
|
0.080 | GeneticVariation | BEFREE | Three ABCB1 SNPs (C1236T, G2677T, and C3435T) were genotyped in 100 Egyptian patients with CML undergoing IM therapy using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay. | 25301112 | 2014 |
||||
|
0.080 | GeneticVariation | BEFREE | We investigated the MDR1 T1236C, G 2677T/A, and C3435T polymorphism in 52 patients with chronic myeloid leukemia treated with imatinib. | 20204543 | 2011 |